NO20082156L - Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMG-CoA-reduktaseinhibitor og et stabiliserende middel - Google Patents
Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMG-CoA-reduktaseinhibitor og et stabiliserende middelInfo
- Publication number
- NO20082156L NO20082156L NO20082156A NO20082156A NO20082156L NO 20082156 L NO20082156 L NO 20082156L NO 20082156 A NO20082156 A NO 20082156A NO 20082156 A NO20082156 A NO 20082156A NO 20082156 L NO20082156 L NO 20082156L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitor
- hmg
- coa reductase
- cholesterol absorption
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Farmasøytisk preparat omfattende en kolesterolabsorpsjonsinhibitor og en HMG-CoA-reduktaseinhibitor, én eller flere antioksidanter, mikrokrystallinsk cellulose, hydroksylpropylmetylcellulose, magnesiumstearat og laktose. Preparatet inneholder askorbinsyre for å oppnå den ønskede stabilitet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39869102P | 2002-07-26 | 2002-07-26 | |
PCT/US2003/022889 WO2004010993A1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082156L true NO20082156L (no) | 2005-04-25 |
Family
ID=31188454
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051033A NO20051033L (no) | 2002-07-26 | 2005-02-25 | Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMF-CoA-reduktaseinhibitor og et stabiliserende middel |
NO20082156A NO20082156L (no) | 2002-07-26 | 2008-05-08 | Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMG-CoA-reduktaseinhibitor og et stabiliserende middel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051033A NO20051033L (no) | 2002-07-26 | 2005-02-25 | Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMF-CoA-reduktaseinhibitor og et stabiliserende middel |
Country Status (39)
Country | Link |
---|---|
US (4) | US7229982B2 (no) |
EP (2) | EP1992343A1 (no) |
JP (2) | JP2005538104A (no) |
KR (2) | KR20080070089A (no) |
CN (2) | CN101069684A (no) |
AR (2) | AR040588A1 (no) |
AT (1) | ATE393628T1 (no) |
AU (2) | AU2003261217B2 (no) |
BR (1) | BR0312933A (no) |
CA (1) | CA2493076A1 (no) |
CR (1) | CR9767A (no) |
DE (1) | DE60320652T2 (no) |
DK (1) | DK1531805T3 (no) |
EA (1) | EA008888B1 (no) |
EC (2) | ECSP055573A (no) |
ES (1) | ES2303603T3 (no) |
GE (1) | GEP20084443B (no) |
GT (2) | GT200300149A (no) |
HK (1) | HK1080384A1 (no) |
HR (2) | HRP20050081A2 (no) |
IL (2) | IL166279A0 (no) |
IS (1) | IS7637A (no) |
MA (1) | MA27289A1 (no) |
ME (3) | ME00008B (no) |
MX (1) | MXPA05001004A (no) |
MY (1) | MY148689A (no) |
NO (2) | NO20051033L (no) |
NZ (1) | NZ537611A (no) |
PA (1) | PA8577901A1 (no) |
PE (1) | PE20050128A1 (no) |
PL (1) | PL375065A1 (no) |
PT (1) | PT1531805E (no) |
RS (2) | RS20080072A (no) |
SI (1) | SI1531805T1 (no) |
TN (1) | TNSN05022A1 (no) |
TW (2) | TW200412944A (no) |
UA (1) | UA82489C2 (no) |
WO (1) | WO2004010993A1 (no) |
ZA (1) | ZA200500196B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
DE602004008100T2 (de) * | 2003-11-10 | 2008-04-30 | Microbia Inc., Cambridge | 4-biarylyl-1-phenylazetidin-2-one |
DE602004029715D1 (de) | 2003-12-23 | 2010-12-02 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
US20070275075A1 (en) * | 2006-03-06 | 2007-11-29 | Ilan Zalit | Ezetimibe compositions |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
ES2622576T3 (es) | 2006-06-19 | 2017-07-06 | Alpharma Pharmaceuticals Llc | Composiciones farmacéuticas |
CN1994296B (zh) * | 2006-08-02 | 2010-06-16 | 浙江京新药业股份有限公司 | 一种含有辛伐他汀的药物制剂 |
GB0713707D0 (en) | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
WO2009016358A2 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
CN101938995A (zh) * | 2007-12-17 | 2011-01-05 | 克卡制药新梅斯托股份公司 | 包含非微粉化依泽替米贝微粒的悬浮液 |
US20090233898A1 (en) * | 2008-03-11 | 2009-09-17 | Glenmark Generics Ltd | Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe |
TR200806302A2 (tr) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. |
EP2168573A1 (en) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
EP2204170A1 (en) * | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
WO2010066687A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Stabalized statin-comprising compositions |
EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
EP2448919A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
WO2011002424A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation |
EP2448564A2 (en) * | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
KR101302243B1 (ko) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
CN101978953A (zh) * | 2010-10-11 | 2011-02-23 | 上海交通大学 | 基于易吸湿性辅料的固体制剂 |
EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
KR20160031038A (ko) | 2011-02-02 | 2016-03-21 | 알파마 파머슈티컬스 엘엘씨 | 오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물 |
CN102266323B (zh) * | 2011-08-04 | 2013-03-27 | 海南锦瑞制药股份有限公司 | 依折麦布和辛伐他汀组合物及其制备方法 |
WO2013034436A1 (de) * | 2011-09-08 | 2013-03-14 | Hexal Ag | Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin |
WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
PL2844233T3 (pl) * | 2012-05-01 | 2020-09-07 | Althera Life Sciences, Llc | Preparat w postaci tabletki do stosowania doustnego składający się ze stałego połączenia rosuwastatyny i ezetymibu w leczeniu hiperlipidemii i chorób sercowo-naczyniowych |
RU2547574C2 (ru) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Лекарственная форма гиполипидемического действия и способ ее изготовления |
CN103585146B (zh) * | 2013-11-09 | 2015-04-01 | 北京中申专利科技有限公司 | 辛伐他汀的药物组合物 |
TWI586380B (zh) * | 2013-12-18 | 2017-06-11 | 夢製藥公司 | 包含HMG-CoA還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑 |
CN104306348B (zh) * | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | 一种辛伐他汀片及其制备方法 |
CN108348491A (zh) * | 2015-11-06 | 2018-07-31 | 燿石治疗公司 | 治疗混合性血脂异常 |
CN106937952A (zh) * | 2016-01-04 | 2017-07-11 | 重庆华邦制药有限公司 | 依折麦布和辛伐他汀的制剂 |
EP3281649A1 (en) * | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Wetting agent formulation |
JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
WO2019101150A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布片剂及其制备方法 |
TWI760067B (zh) * | 2020-08-13 | 2022-04-01 | 友霖生技醫藥股份有限公司 | 固態口服醫藥組成物 |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
CN112168801A (zh) * | 2020-10-22 | 2021-01-05 | 哈药集团技术中心 | 一种辛伐他汀片的制备方法 |
CN115227659B (zh) * | 2022-08-19 | 2023-05-02 | 北京百奥药业有限责任公司 | 一种依折麦布辛伐他汀组合物及其制备方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
WO1988005296A2 (en) | 1987-01-27 | 1988-07-28 | Warner-Lambert Company | Lpid regulating compositions |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
MY131273A (en) | 1991-07-23 | 2007-07-31 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
KR100281609B1 (ko) * | 1991-12-27 | 2001-02-15 | 폴락 돈나 엘. | 유효 제제를 포함하는 분산액의 동일 반응계내 생성 및 방출을 조절하는 약물 전달 장치 |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
JPH06247854A (ja) * | 1993-02-24 | 1994-09-06 | Ss Pharmaceut Co Ltd | アスコルビン酸含有組成物 |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
CA2191455A1 (en) * | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
EP0782451A1 (en) | 1994-09-20 | 1997-07-09 | Pfizer Inc. | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor |
US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
DE69621952T2 (de) * | 1995-10-31 | 2003-01-16 | Schering Corp | Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel |
CA2251972A1 (en) * | 1996-04-17 | 1997-10-23 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6673831B1 (en) * | 1996-04-17 | 2004-01-06 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
AU4326197A (en) | 1996-07-09 | 1998-02-02 | Merck & Co., Inc. | Pharmaceutical compositions |
FR2751540B1 (fr) * | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
US5952003A (en) | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6251852B1 (en) | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6235706B1 (en) | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
AU4699099A (en) | 1998-06-24 | 2000-01-10 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
JP2002518448A (ja) | 1998-06-24 | 2002-06-25 | メルク エンド カムパニー インコーポレーテッド | 高血中コレステロールを治療する組成物および方法 |
US6099865A (en) | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
JP2000109882A (ja) * | 1998-10-01 | 2000-04-18 | Nof Corp | 油性粉末、製造方法および用途 |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
AU764048B2 (en) | 1999-03-08 | 2003-08-07 | Merck & Co., Inc. | Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
JP2002538202A (ja) | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
JP2002538189A (ja) | 1999-03-10 | 2002-11-12 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ−2インヒビターの投与方法と組成物 |
JP2000302672A (ja) * | 1999-04-16 | 2000-10-31 | Taisho Pharmaceut Co Ltd | 咀嚼可能な被覆錠剤 |
JP3732039B2 (ja) * | 1999-05-21 | 2006-01-05 | 三菱化学フーズ株式会社 | 錠剤用組成物 |
DZ3179A1 (fr) | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Compositions pharmaceutiques à base de beta-carboline. |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
WO2001041770A2 (en) | 1999-12-08 | 2001-06-14 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
AU2276801A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
DK1267880T4 (da) | 2000-02-29 | 2010-05-17 | Bristol Myers Squibb Co | Entecavir-formulering med lav dosis og anvendelse deraf |
JP2004508347A (ja) * | 2000-09-06 | 2004-03-18 | メルク エンド カムパニー インコーポレーテッド | シンバスタチンのジヒドロキシ開環酸塩 |
SI1593670T1 (sl) * | 2000-12-20 | 2007-12-31 | Schering Corp | S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
MXPA03005923A (es) * | 2000-12-28 | 2004-01-26 | Kissei Pharmaceuticals Co Ltd | Derivados de glupopiranosiloxipirazol y su uso en medicinas. |
ES2287250T3 (es) | 2001-01-26 | 2007-12-16 | Schering Corporation | Combinaciones de secuestrante(s) de acidos biliares e inhibidor(es) de la absorcion de esteroles y tratamientos para indicaciones vasculares. |
JP2004517920A (ja) | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ |
PL205343B1 (pl) | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu |
SI1353696T1 (sl) | 2001-01-26 | 2007-04-30 | Schering Corp | Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije |
CZ20032031A3 (cs) | 2001-01-26 | 2003-12-17 | Schering Corporation | Farmaceutický prostředek |
ES2245733T3 (es) | 2001-03-28 | 2006-01-16 | Schering Corporation | Sintesis enantioselectiva de compuestos intermedios de azetidinona. |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
-
2003
- 2003-07-16 AR AR20030102560A patent/AR040588A1/es unknown
- 2003-07-17 MY MYPI20032695A patent/MY148689A/en unknown
- 2003-07-21 PE PE2003000726A patent/PE20050128A1/es not_active Application Discontinuation
- 2003-07-22 AU AU2003261217A patent/AU2003261217B2/en not_active Ceased
- 2003-07-22 GT GT200300149A patent/GT200300149A/es unknown
- 2003-07-22 US US10/625,004 patent/US7229982B2/en not_active Expired - Fee Related
- 2003-07-22 JP JP2004524692A patent/JP2005538104A/ja active Pending
- 2003-07-22 EA EA200500279A patent/EA008888B1/ru not_active IP Right Cessation
- 2003-07-22 UA UAA200501756A patent/UA82489C2/uk unknown
- 2003-07-22 EP EP08103776A patent/EP1992343A1/en not_active Withdrawn
- 2003-07-22 GE GEAP8662A patent/GEP20084443B/en unknown
- 2003-07-22 RS RSP-2008/0072A patent/RS20080072A/sr unknown
- 2003-07-22 ME MEP-2008-47A patent/ME00008B/me unknown
- 2003-07-22 PL PL03375065A patent/PL375065A1/xx not_active Application Discontinuation
- 2003-07-22 DK DK03771709T patent/DK1531805T3/da active
- 2003-07-22 BR BR0312933-0A patent/BR0312933A/pt not_active IP Right Cessation
- 2003-07-22 RS YUP-2005/0061A patent/RS50419B/sr unknown
- 2003-07-22 AT AT03771709T patent/ATE393628T1/de not_active IP Right Cessation
- 2003-07-22 DE DE60320652T patent/DE60320652T2/de not_active Revoked
- 2003-07-22 NZ NZ537611A patent/NZ537611A/en not_active IP Right Cessation
- 2003-07-22 IL IL16627903A patent/IL166279A0/xx unknown
- 2003-07-22 KR KR1020087017824A patent/KR20080070089A/ko not_active Application Discontinuation
- 2003-07-22 EP EP03771709A patent/EP1531805B1/en not_active Revoked
- 2003-07-22 MX MXPA05001004A patent/MXPA05001004A/es active IP Right Grant
- 2003-07-22 KR KR1020057001458A patent/KR20050045993A/ko not_active Application Discontinuation
- 2003-07-22 ME MEP-2008-308A patent/ME00207B/me unknown
- 2003-07-22 PT PT03771709T patent/PT1531805E/pt unknown
- 2003-07-22 CA CA002493076A patent/CA2493076A1/en not_active Abandoned
- 2003-07-22 ME MEP-308/08A patent/MEP30808A/xx unknown
- 2003-07-22 CN CNA2007100850256A patent/CN101069684A/zh active Pending
- 2003-07-22 PA PA20038577901A patent/PA8577901A1/es unknown
- 2003-07-22 ES ES03771709T patent/ES2303603T3/es not_active Expired - Lifetime
- 2003-07-22 CN CNB038178443A patent/CN1310643C/zh not_active Expired - Fee Related
- 2003-07-22 GT GT200300149AK patent/GT200300149AA/es unknown
- 2003-07-22 WO PCT/US2003/022889 patent/WO2004010993A1/en active Application Filing
- 2003-07-22 SI SI200331222T patent/SI1531805T1/sl unknown
- 2003-07-25 TW TW092120442A patent/TW200412944A/zh unknown
- 2003-07-25 TW TW097131985A patent/TW200906388A/zh unknown
-
2005
- 2005-01-10 IS IS7637A patent/IS7637A/is unknown
- 2005-01-10 ZA ZA200500196A patent/ZA200500196B/en unknown
- 2005-01-25 EC EC2005005573A patent/ECSP055573A/es unknown
- 2005-01-25 HR HR20050081A patent/HRP20050081A2/xx not_active Application Discontinuation
- 2005-01-26 TN TNP2005000022A patent/TNSN05022A1/en unknown
- 2005-02-11 MA MA28095A patent/MA27289A1/fr unknown
- 2005-02-25 NO NO20051033A patent/NO20051033L/no unknown
-
2006
- 2006-01-12 HK HK06100504A patent/HK1080384A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 US US11/716,595 patent/US20070160666A1/en not_active Abandoned
-
2008
- 2008-02-26 CR CR9767A patent/CR9767A/es unknown
- 2008-02-28 EC EC20080055732008005573A patent/ECSP085573A/es unknown
- 2008-03-12 US US12/047,223 patent/US20080275020A1/en not_active Abandoned
- 2008-05-08 NO NO20082156A patent/NO20082156L/no not_active Application Discontinuation
- 2008-05-11 IL IL191348A patent/IL191348A0/en unknown
- 2008-06-09 JP JP2008150227A patent/JP2008291034A/ja not_active Withdrawn
- 2008-06-17 AR ARP080102576A patent/AR067030A2/es not_active Application Discontinuation
- 2008-10-16 HR HR20080518A patent/HRP20080518A2/xx not_active Application Discontinuation
-
2009
- 2009-02-26 AU AU2009200768A patent/AU2009200768A1/en not_active Abandoned
- 2009-05-26 US US12/472,021 patent/US7718643B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082156L (no) | Preparat omfattende en kolesterolabsorpsjonsinhibitor, en HMG-CoA-reduktaseinhibitor og et stabiliserende middel | |
WO2005069865A3 (en) | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | |
SG155188A1 (en) | Pyrrole derivatives as pharmaceutical agents | |
IS7764A (is) | Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar | |
WO2006042138A8 (en) | Systems and methods for ex-vivo organ care | |
NO20054369L (no) | Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse | |
WO2003080070A3 (en) | Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer | |
TW200740429A (en) | Methods and dosage forms for reducing side effects of carbamate compounds | |
AR038207A1 (es) | Composicion farmaceutica dispersable oralmente de agomelatina | |
MX2007006279A (es) | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa. | |
WO2005105081A3 (en) | Therapeutic formulations of desoxyepothilones | |
BRPI0507859A (pt) | uso dos inibidores da colinesterase | |
NO20063707L (no) | Kompresjons-belagte tabeletter og fremstilling derav | |
MY139425A (en) | Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol | |
WO2006102126A3 (en) | Inhibitors of isoprenylcysteine carboxyl methyltransferase | |
PL378106A1 (pl) | Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem | |
WO2006076580A3 (en) | A method of modulating t cell functioning | |
DOP2003000676A (es) | Formulacion farmaceutica | |
CR7658A (es) | Composicion que comprende un inhibidor de la absorcion del colesterol un inhibidor de la hmg-coa y un agente estabilizador | |
PT1490049E (pt) | Citalopram para o tratamento da pre3ssao sanguinia elevada. | |
IL160602A0 (en) | Polysubstituted indan-1-ol systems, processes for their preparation and their use as pharmaceuticals | |
AUPS040602A0 (en) | Sight and sound retarding, mask for aiding sleep | |
WO2007108001A3 (en) | Ligament remodeling | |
MY155041A (en) | Methods and dosage forms for reducing side effects of benzisozazole derivatives | |
DOP2008000034A (es) | Formulacion farmaceutica que comprende simvastatina y ezetimiba |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |